So it's a brilliant question and is one that I have given a great deal of thought to recently. I think currently today, with adjuvant therapy volume up and perioperative treatment volume up, we are improving outcomes in muscle invasive disease. But it's still the case that cystectomy has a very important role to play. I believe cystectomy still is the standard of care today, although many colleagues of mine in north America and specifically in the UK think trimodality therapy with DTRBT chemo radiation is equivalent to cystectomy. When I asked my Uromigos' colleagues , it scores one point nine suggests that people feel it's okay, but maybe not quite as good as cystectomy. Most people in the UK, at least, are offered the choice between cystectomy or trimodality therapy, but that's not the global standard. Global standard is still to give cystectomy. But when EV-304 , EV-303 and the VOLGA trial which deliver durvalumab，tremelimumab，enfortumab vedotin in triplets，when these trials read out over the next eighteen months, what we will see，in my opinion，is a transformation. 

Well, instead of cystectomy and radiation therapy, we can give EV+Pembro, and you got 60% chance of going into a complete response. And once you're in that complete response, why would you wanna give radio therapy or do surgery? I think patients want to keep going with immune therapy for a year. Those frail patients who before we were saying there's no good treatment option, we can't just do the chemo therapy. Those patients whose kidney function is not great, we can't have neoadjuvant chemotherapy. All of these patients, we're going give enfortumab vedotin with pembrolizumab or durva+treme. We're gonna see the cancers in many cases disappear. And in many cases we won’t do cystectomies, but we won't need to do other interventions like radiation therapy. So I see there being a transformation in bladder cancer. We will end up giving ADCs, the new therapy. We won't be doing surgery on majority of patients, particularly those who are frail. We won't be doing a role for radiation therapy either. We will need to follow those patients carefully to make sure there's no local recurrence of disease or a local new tumor. But it is apparent to me that perhaps this time next year, or the year after, the conversation which I had there will be completely different. I will be looking at this disease differently.